Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Public Sector Pension Investment Board

Public Sector Pension Investment Board grew its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 77.7% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 3,841 shares of the biopharmaceutical company’s stock after acquiring an additional 1,679 shares during the quarter. Public Sector Pension Investment Board’s holdings in Regeneron Pharmaceuticals were worth $4,037,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. EverSource Wealth Advisors LLC grew its holdings in shares of Regeneron Pharmaceuticals by 23.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 635 shares of the biopharmaceutical company’s stock worth $685,000 after purchasing an additional 119 shares during the period. Gabelli Funds LLC grew its stake in Regeneron Pharmaceuticals by 1.8% during the second quarter. Gabelli Funds LLC now owns 1,893 shares of the biopharmaceutical company’s stock worth $1,990,000 after buying an additional 34 shares during the period. Itau Unibanco Holding S.A. purchased a new stake in Regeneron Pharmaceuticals during the second quarter worth approximately $42,000. Fidelis Capital Partners LLC increased its position in shares of Regeneron Pharmaceuticals by 27.1% in the second quarter. Fidelis Capital Partners LLC now owns 534 shares of the biopharmaceutical company’s stock worth $570,000 after acquiring an additional 114 shares in the last quarter. Finally, Epoch Investment Partners Inc. raised its stake in shares of Regeneron Pharmaceuticals by 57.7% in the 2nd quarter. Epoch Investment Partners Inc. now owns 163,296 shares of the biopharmaceutical company’s stock valued at $171,629,000 after acquiring an additional 59,745 shares during the period. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several analysts recently issued reports on the company. Wells Fargo & Company reiterated an “overweight” rating and issued a $1,200.00 price target on shares of Regeneron Pharmaceuticals in a report on Monday. Royal Bank of Canada dropped their target price on Regeneron Pharmaceuticals from $1,282.00 to $1,252.00 and set an “outperform” rating on the stock in a report on Tuesday. Piper Sandler upped their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the stock an “overweight” rating in a report on Friday, August 23rd. Canaccord Genuity Group reiterated a “buy” rating and set a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Finally, BMO Capital Markets restated an “outperform” rating and issued a $1,300.00 target price on shares of Regeneron Pharmaceuticals in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $1,118.62.

Insider Transactions at Regeneron Pharmaceuticals

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a legal filing with the SEC, which is available through this link. In related news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the sale, the chief financial officer now owns 15,305 shares of the company’s stock, valued at approximately $18,447,575.65. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Marion Mccourt sold 1,137 shares of the company’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,047.11, for a total value of $1,190,564.07. Following the transaction, the executive vice president now owns 12,931 shares of the company’s stock, valued at $13,540,179.41. The disclosure for this sale can be found here. In the last three months, insiders have sold 9,270 shares of company stock worth $10,695,833. 7.48% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Trading Up 0.9 %

Shares of NASDAQ REGN opened at $1,039.96 on Friday. The company has a quick ratio of 4.62, a current ratio of 5.44 and a debt-to-equity ratio of 0.10. The stock’s 50 day moving average price is $1,129.87 and its two-hundred day moving average price is $1,033.99. Regeneron Pharmaceuticals, Inc. has a 52-week low of $769.19 and a 52-week high of $1,211.20. The stock has a market capitalization of $114.59 billion, a P/E ratio of 30.72, a PEG ratio of 3.72 and a beta of 0.12.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $8.93 by $2.63. The business had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. Regeneron Pharmaceuticals had a return on equity of 16.80% and a net margin of 32.04%. The business’s revenue was up 12.3% compared to the same quarter last year. During the same period in the prior year, the company posted $8.79 EPS. On average, analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.8 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.